These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 20812149)

  • 1. Small-molecule PARP modulators--current status and future therapeutic potential.
    Penning TD
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
    Jones P; Altamura S; Boueres J; Ferrigno F; Fonsi M; Giomini C; Lamartina S; Monteagudo E; Ontoria JM; Orsale MV; Palumbi MC; Pesci S; Roscilli G; Scarpelli R; Schultz-Fademrecht C; Toniatti C; Rowley M
    J Med Chem; 2009 Nov; 52(22):7170-85. PubMed ID: 19873981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
    Gandhi VB; Luo Y; Liu X; Shi Y; Klinghofer V; Johnson EF; Park C; Giranda VL; Penning TD; Zhu GD
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1023-6. PubMed ID: 20045315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors in cancer therapy: an update.
    Papeo G; Casale E; Montagnoli A; Cirla A
    Expert Opin Ther Pat; 2013 Apr; 23(4):503-14. PubMed ID: 23379721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors.
    Iwashita A; Hattori K; Yamamoto H; Ishida J; Kido Y; Kamijo K; Murano K; Miyake H; Kinoshita T; Warizaya M; Ohkubo M; Matsuoka N; Mutoh S
    FEBS Lett; 2005 Feb; 579(6):1389-93. PubMed ID: 15733846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
    Ferraris DV
    J Med Chem; 2010 Jun; 53(12):4561-84. PubMed ID: 20364863
    [No Abstract]   [Full Text] [Related]  

  • 15. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
    Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
    J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
    Putt KS; Hergenrother PJ
    Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
    Bryant HE; Helleday T
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):959-61. PubMed ID: 15506935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibition as a prototype for synthetic lethal screens.
    Liu X
    Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors: will the new class of drugs match the hype?
    Tuma RS
    J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
    Kim DH; Sim T
    Arch Pharm Res; 2012 Mar; 35(4):605-15. PubMed ID: 22553052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.